Business Wire

Inspur Information Releases the A6 Server Portfolio with Full Support for 3 rd Gen AMD EPYC TM Milan Processors

Share

Inspur Information, a leading IT infrastructure provider, launched the new A6 server line that supports 3rd Gen AMD® EPYCTM Milan/Milan-X 7003 series processors. The A6 server line features multi-core capabilities that show outstanding performance leaps compared to previous generation of servers with an up to 28% performance increase in SPEC performance test. The A6 server line will serve as the foundation for compute-intensive applications in the enterprise scenarios, such as big data, multi-cloud and other high-demand computing applications.

“By launching the brand new A6 servers, Inspur aims to deliver better compute performance for reliable and efficient business support. The Inspur A6 server series features best-in-class performance, energy efficiency and scalability to address the enormous computing challenges imposed by the era of big data and digital transformation”, said Ricky Zhao, Deputy General Manager of Server Product Line and General Manager of Datacenter Product Line, Inspur Information.

“AMD has been collaborating with Inspur to deliver innovative and high-performance products to the market”, said Roger Benson, Senior Director of AMD. “The new A6 server line powered by AMD EPYCTM Milan/Milan-X 7003 series processors represents the latest achievement by AMD and Inspur. With multi-core configurations and a series of performance optimizations, this server solution will unleash more possibilities for handling complex and compute-intensive workloads.”

A6 servers showcase outstanding performance with multiple cores with a high-base frequency, providing industry-leading single core capabilities. Storage density and IOPS (input/output operations per second) are increased by more than threefold. With the precision engineering and multi-level security mechanisms, A6 servers are more intelligent, easy-to-use and safer. They ensure efficient and care-free operation. It is designed with open computing standards, such as the ORS6000E rack.

A6 servers are designed to provide ultimate performance

NF3180A6/ NF3280A6 is a 1U/2U 1S rack server based on 3rd Gen AMD® EPYCTM Milan processors. Powered by multiple cores with a high-base frequency, it can serve as a high-density and cost-effective rack server that delivers strong computing power comparable to traditional dual-socket servers. With the addition of flexible expansion, it can fulfill the specific requirements for cloud computing, distributed storage, big data, CDN, video transcoding, in-memory database and virtualization scenarios.

Inspur NF5180A6/NF5280A6, powered by 3rd Gen AMD® EPYCTM processors, is a high-density dual-socket server that offers strong computing performance, ecological compatibility and configuration flexibility. This server features high quality and strong reliability, which makes it the ideal choice for a variety of complicated workloads, especially data processing, virtualization, high performance and cloud computing.

Inspur i24A6 is a 2U4N multi-node server adopting AMD EPYC™ 7002/7003 processors. It has 24 storage drives, multiple network options, and 8x 3200 MHz RDIMM/LRDIMM. It is tailored for high-performance computing and hyper-scale, and other tasks that require high core counts, large storage capacity and flexible I/O solutions.

Inheriting the design DNA of Inspur Information’s renowned server products, the A6server line represents industry-leading performance, design and security. The line will serve as an engine to promote industrial AI and digital transformation by offering a foundation for a variety of key scenarios including multi-cloud, high-performance computing and edge computing.

About Inspur Information

Inspur Information is a leading provider of data center infrastructure, cloud computing, and AI solutions. It is the world’s 2nd largest server manufacturer. Through engineering and innovation, Inspur Information delivers cutting-edge computing hardware design and extensive product offerings to address important technology sectors such as open computing, cloud data center, AI, and deep learning. Performance-optimized and purpose-built, our world-class solutions empower customers to tackle specific workloads and real-world challenges. To learn more, visit https://www.inspursystems.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Fiona Liu
PR Manager
Inspur Information
liuxuan01@inspur.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom